Ange Wang1, Heather A Wakelee2, Aaron K Aragaki3, Jean Y Tang4, Allison W Kurian2,5, JoAnn E Manson6, Marcia L Stefanick7. 1. Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, 94305, USA. angewang@stanford.edu. 2. Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. 3. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 4. Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA. 5. Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA. 6. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 7. Department of Medicine, Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA.
Abstract
PURPOSE OF REVIEW: Statins are one of the most widely prescribed drug classes in the USA. This review aims to summarize recent research on the relationship between statin use and cancer outcomes, in the context of clinical guidelines for statin use in patients with cancer or who are at high risk for cancer. RECENT FINDINGS: A growing body of research has investigated the relationship between statins and cancer with mixed results. Cancer incidence has been more extensively studied than cancer survival, though results are inconsistent as some large meta-analyses have not found an association, while other studies have reported improved cancer outcomes with the use of statins. Additionally, two large studies reported increased all-cancer survival with statin use. Studies on specific cancer types in relation to cancer use have also been mixed, though the most promising results appear to be found in gastrointestinal cancers. Few studies have reported an increased risk of cancer incidence or decreased survival with statin use, though this type of association has been more commonly reported for cutaneous cancers. The overall literature on statins in relation to cancer incidence and survival is mixed, and additional research is warranted before any changes in clinical guidelines can be recommended. Future research areas include randomized controlled trials, studies on specific cancer types in relation to statin use, studies on populations without clinical indication for statins, elucidation of underlying biological mechanisms, and investigation of different statin types. However, studies seem to suggest that statins may be protective and are not likely to be harmful in the setting of cancer, suggesting that cancer patients who already take statins should not have this medication discontinued.
PURPOSE OF REVIEW: Statins are one of the most widely prescribed drug classes in the USA. This review aims to summarize recent research on the relationship between statin use and cancer outcomes, in the context of clinical guidelines for statin use in patients with cancer or who are at high risk for cancer. RECENT FINDINGS: A growing body of research has investigated the relationship between statins and cancer with mixed results. Cancer incidence has been more extensively studied than cancer survival, though results are inconsistent as some large meta-analyses have not found an association, while other studies have reported improved cancer outcomes with the use of statins. Additionally, two large studies reported increased all-cancer survival with statin use. Studies on specific cancer types in relation to cancer use have also been mixed, though the most promising results appear to be found in gastrointestinal cancers. Few studies have reported an increased risk of cancer incidence or decreased survival with statin use, though this type of association has been more commonly reported for cutaneous cancers. The overall literature on statins in relation to cancer incidence and survival is mixed, and additional research is warranted before any changes in clinical guidelines can be recommended. Future research areas include randomized controlled trials, studies on specific cancer types in relation to statin use, studies on populations without clinical indication for statins, elucidation of underlying biological mechanisms, and investigation of different statin types. However, studies seem to suggest that statins may be protective and are not likely to be harmful in the setting of cancer, suggesting that cancerpatients who already take statins should not have this medication discontinued.
Authors: Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Eric J Jacobs; Carmen Rodriguez; Kerri A Brady; Cari J Connell; Michael J Thun; Eugenia E Calle Journal: J Natl Cancer Inst Date: 2006-01-04 Impact factor: 13.506
Authors: Jordan Fulcher; Rachel O'Connell; Merryn Voysey; Jonathan Emberson; Lisa Blackwell; Borislava Mihaylova; John Simes; Rory Collins; Adrienne Kirby; Helen Colhoun; Eugene Braunwald; John La Rosa; T R Pedersen; Andrew Tonkin; Barry Davis; Peter Sleight; Maria Grazia Franzosi; Colin Baigent; Anthony Keech Journal: Lancet Date: 2015-01-09 Impact factor: 79.321
Authors: E Dawn Flick; Laurel A Habel; K Arnold Chan; Stephen K Van Den Eeden; Virginia P Quinn; Reina Haque; Endel J Orav; John D Seeger; Marianne C Sadler; Charles P Quesenberry; Barbara Sternfeld; Steven J Jacobsen; Rachel A Whitmer; Bette J Caan Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-10-30 Impact factor: 4.254
Authors: Edward J Mills; Beth Rachlis; Ping Wu; Philip J Devereaux; Paul Arora; Dan Perri Journal: J Am Coll Cardiol Date: 2008-11-25 Impact factor: 24.094
Authors: Ange Wang; Aaron K Aragaki; Jean Y Tang; Allison W Kurian; JoAnn E Manson; Rowan T Chlebowski; Michael Simon; Pinkal Desai; Sylvia Wassertheil-Smoller; Simin Liu; Stephen Kritchevsky; Heather A Wakelee; Marcia L Stefanick Journal: Br J Cancer Date: 2016-06-09 Impact factor: 7.640
Authors: Tawfik Khoury; Amir Mari; Hana Amara; Mohamed Jabaren; Abdulla Watad; Wiliam Nseir; Wisam Sbeit; Mahmud Mahamid Journal: Can J Gastroenterol Hepatol Date: 2019-02-03